Published in Nat Clin Pract Cardiovasc Med on August 01, 2006
Targeting ryanodine receptors for anti-arrhythmic therapy. Acta Pharmacol Sin (2011) 0.88
Rescuing a failing heart: think globally, treat locally. Nat Med (2009) 0.81
HRS policy statement: clinical cardiac electrophysiology fellowship curriculum: update 2011. Heart Rhythm (2011) 0.75
Global changes to the ubiquitin system in Huntington's disease. Nature (2007) 3.91
Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu Rev Biochem (2001) 3.64
Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem J (2002) 3.29
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
CaMKII tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of Ca2+ signals for facilitation. J Cell Biol (2005) 2.47
Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron (2003) 2.36
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35
Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol (2007) 2.07
Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci (2006) 2.05
The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem (2001) 1.99
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
A mechanism for Ca2+/calmodulin-dependent protein kinase II clustering at synaptic and nonsynaptic sites based on self-association. J Neurosci (2005) 1.78
Protein standard absolute quantification (PSAQ) method for the measurement of cellular ubiquitin pools. Nat Methods (2011) 1.60
An ultrasensitive Ca2+/calmodulin-dependent protein kinase II-protein phosphatase 1 switch facilitates specificity in postsynaptic calcium signaling. Proc Natl Acad Sci U S A (2003) 1.57
A mechanism for tunable autoinhibition in the structure of a human Ca2+/calmodulin- dependent kinase II holoenzyme. Cell (2011) 1.56
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48
Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. J Biol Chem (2002) 1.44
Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol (2007) 1.44
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene (2004) 1.38
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res (2007) 1.33
Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol (2012) 1.32
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res (2006) 1.31
Chemical quenched flow kinetic studies indicate an intraholoenzyme autophosphorylation mechanism for Ca2+/calmodulin-dependent protein kinase II. J Biol Chem (2002) 1.30
Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J (2002) 1.23
Promiscuous protein biotinylation by Escherichia coli biotin protein ligase. Protein Sci (2004) 1.22
Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation. Nat Struct Mol Biol (2010) 1.21
Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis. J Biol Chem (2001) 1.16
Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma (2008) 1.11
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol (2007) 1.10
Calcium/calmodulin-dependent protein kinase II (CaMKII) localization acts in concert with substrate targeting to create spatial restriction for phosphorylation. J Biol Chem (2004) 1.08
p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther (2007) 1.06
Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res (2004) 1.05
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res (2004) 1.05
A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. J Pharmacol Exp Ther (2006) 1.04
Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A (2002) 1.04
In search of cellular immunophenotypes in the blood of children with autism. PLoS One (2011) 1.04
A p38 mitogen-activated protein kinase inhibitor arrests active alveolar bone loss in a rat periodontitis model. J Periodontol (2007) 1.04
Deconvoluting post-transplant immunity: cell subset-specific mapping reveals pathways for activation and expansion of memory T, monocytes and B cells. PLoS One (2010) 1.03
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res (2008) 1.00
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res (2006) 0.98
Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol (2012) 0.97
Activation-triggered subunit exchange between CaMKII holoenzymes facilitates the spread of kinase activity. Elife (2013) 0.96
Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. Eur J Pharmacol (2006) 0.91
Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain. Pharmacol Biochem Behav (2008) 0.91
Structural studies on the regulation of Ca2+/calmodulin dependent protein kinase II. Curr Opin Struct Biol (2013) 0.90
8OHdG is not a biomarker for Huntington disease state or progression. Neurology (2013) 0.88
Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J Diabetes Complications (2010) 0.88
Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res (2007) 0.88
p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res (2009) 0.87
Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation. Eur J Pharmacol (2008) 0.86
p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol (2004) 0.85
Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo. J Neurosci Res (2004) 0.84
Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma. J Asthma Allergy (2008) 0.84
Pyrimidine-based inhibitors of CaMKIIdelta. Bioorg Med Chem Lett (2008) 0.80
P38alpha-selective mitogen-activated protein kinase inhibitor for improvement of cultured human islet recovery. Pancreas (2010) 0.79
CaMKII structure--an elegant design. Cell (2005) 0.78
Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase. Pharmacology (2008) 0.78
Expression of human apolipoprotein E downregulates amyloid precursor protein-induced ischemic susceptibility. Stroke (2002) 0.77
Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig. J Inflamm Res (2010) 0.76
p38 MAPK inhibition reduces diabetes-induced impairment of wound healing. Diabetes Metab Syndr Obes (2009) 0.76
Correction: Activation-triggered subunit exchange between CaMKII holoenzymes facilitates the spread of kinase activity. Elife (2014) 0.75